UBS Group Cuts Axon Enterprise (NASDAQ:AXON) Price Target to $610.00

Axon Enterprise (NASDAQ:AXON) had its target price decreased by UBS Group from $840.00 to $610.00 in a report released on Wednesday morning,Benzinga reports. UBS Group currently has a neutral rating on the biotechnology company’s stock.

AXON has been the subject of several other reports. Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday. Piper Sandler dropped their price target on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research report on Wednesday. Craig Hallum raised Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price target for the company in a research note on Tuesday, August 5th. Bank of America boosted their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Finally, The Goldman Sachs Group dropped their target price on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a report on Wednesday. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $810.71.

Axon Enterprise Trading Up 2.6%

Shares of AXON opened at $602.51 on Wednesday. Axon Enterprise has a twelve month low of $469.24 and a twelve month high of $885.91. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $47.30 billion, a P/E ratio of 148.77, a PEG ratio of 29.49 and a beta of 1.45. The firm’s 50-day moving average is $719.61 and its two-hundred day moving average is $734.79.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s revenue was up 30.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.45 earnings per share. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Axon Enterprise will post 5.8 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other news, President Joshua Isner sold 15,919 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the completion of the transaction, the president owned 238,379 shares of the company’s stock, valued at $177,892,712.54. This represents a 6.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeri Williams sold 100 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total transaction of $75,254.00. Following the completion of the sale, the director directly owned 1,416 shares in the company, valued at $1,065,596.64. This represents a 6.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 59,932 shares of company stock worth $45,115,616 in the last three months. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wealth Alliance LLC boosted its holdings in shares of Axon Enterprise by 3.2% in the 3rd quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 18 shares during the last quarter. Synergy Investment Management LLC acquired a new stake in shares of Axon Enterprise during the 3rd quarter worth $323,000. NewEdge Wealth LLC increased its holdings in shares of Axon Enterprise by 53.9% during the 3rd quarter. NewEdge Wealth LLC now owns 1,367 shares of the biotechnology company’s stock worth $981,000 after buying an additional 479 shares during the last quarter. CenterBook Partners LP raised its position in shares of Axon Enterprise by 78.0% in the 3rd quarter. CenterBook Partners LP now owns 7,208 shares of the biotechnology company’s stock worth $5,173,000 after buying an additional 3,159 shares during the period. Finally, Advisors Capital Management LLC purchased a new position in shares of Axon Enterprise in the 3rd quarter worth $246,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.